植物油对大鼠应激性胃粘膜损伤的保护作用

将大鼠捆缚后置于4℃冰箱3h,造成应激性胃粘膜损伤,损伤程度用损伤指数表示:(1)在应激前3h 用0.5、1.0、2.Oml 的花生油灌胃,使损伤指数从对照的18.8—22.6降为6.8—7.0,P<0.01,但当花生油用量降至0.25ml 时,其保护作用不明显;(2)在应激前0.5、1.5、2.5和3.5h用1.0ml 花生油灌胃,也均有保护作用,(3)菜籽油或油酸有类似花生油的抗胃粘膜损伤作用,而且油酸的作用比花生油更显著,但30%甘油却无效;(4)将1.0ml 花生油注入空肠,具有与灌胃相似的保护作用;(5)在大鼠应激前1.5h 肌注消炎痛(10mg/kg),并不能阻断花生油的保护作用。以上结果表明,花生油等植物油能够通过其脂肪酸成分作用于小肠而产生对抗应激性胃粘膜损伤的作用。这种保护作用的机理不明,但似与前列腺素无关。     

油酸对消炎痛引起的胃粘膜损伤大鼠胃粘液分泌的影响

本工作研究油酸对消炎痛引起胃粘膜损伤大鼠胃粘液分泌的影响。胃粘液测定采用阿尔新蓝(Alcian blue)与胃液中糖蛋白结合的方法。将1.0ml 油酸注入到结扎幽门的大鼠空肠内,就可引起胃壁粘液及游离粘液分泌量的明显增加。以0.25、0.5和1.0ml 油酸注入到不结扎幽门的大鼠空肠内,也能显著增加胃壁粘液分泌,保护胃粘膜。这两种作用表现着剂量依赖关系。不论以油酸灌胃或注入空肠、回肠,都能明显增加胃壁粘液量,而灌胃的作用比注入肠内更明显。以1.0ml 30%甘油、0.1%乙酸及1/15N HCl 分别注入空肠,都不能刺激胃壁粘液的分泌。上述结果表明,油酸具有刺激胃粘液分泌的作用。因此,加强胃粘液分泌可能对粘膜起到屏障作用,这是油酸保护胃粘膜损伤的机制之一。     

巯基物质在消炎痛诱发大鼠胃粘膜损伤中的作用

本工作研究了巯基物质在消炎痛引起大鼠胃粘膜损伤中的可能作用。在胃粘膜损伤发生过程中、胃粘膜内非蛋白及蛋白结合的巯基物质含量均无明显降低。虽然半胱胺灌胃(132或264μmol)或皮下注射(132μmol)后均明显抑制消炎痛溃疡的发生,其抑制率分别为82％,92％和75％,但同样具有巯基的半胱氨酸却无保护作用。半胱胺(132μmol)皮下注射可使消炎痛大鼠胃酸分泌抑制46％,而灌胃则无此作用。两种途径给予的半胱胺均不影响胃壁结合粘液的分泌。这些结果表明,胃粘膜内巯基物质似不参与消炎痛的致溃疡过程。半胱胺在此种模型上虽有强烈的细胞保护作用,但似乎不是由于其分子上所带的巯基所致。因此,巯基物质在消炎痛引起的胃粘膜损伤模型上没有细胞保护作用。     

胃内PGE和PGF_(2α)介导胃蛋白酶的适应性细胞保护作用的观察

胃粘膜细胞不断合成和释放的前列腺素(PGs),具有很强的细胞保护作用。我们的前一工作表明,预先用胃蛋白酶灌胃,可防止牛磺胆酸所致的胃粘膜坏死的发生,这一保护作用可被消炎痛所阻断;间接提示这种适应性细胞保护的发生机制可能与内源性PGs有关。本文则用放射免疫方法,直接测定了胃粘膜组织PGE和PGF_(2α)含量在不同情况下的变化。结果表明,单纯胃蛋白酶225U,胃蛋白酶150U溶于 0.1N HCl或75单位溶于 0.2N HCl中,提前 15min灌胃,均可防止由0.2N NaOH、0.6N HCl 和无水乙醇所致的胃粘膜坏死的发生,这种保护作用呈明显的量效关系。上述三种配方的胃蛋白酶溶液灌胃后15min,胃粘膜组织PGE和PGF_(2α)含量明显升高,分别为对照组的2.7—2.9倍和1.9—2.5倍;且以PGE含量的上升占优势。进一步观察不同浓度胃蛋白酶溶于生理浓度盐酸中对胃粘膜PG含量的影响发现,胃蛋白酶与胃粘膜组织PGE和PGF_(2α)含量的增加呈现明显的量效关系。这些结果说明,胃蛋白酶作为弱刺激对强酸、强碱和无水乙醇所致的胃粘膜损伤均有保护作用,其作用机制则是通过诱发内源性PGs的合成和释放而实现的。     

消炎痛致胃粘膜损伤时胃组织胺含量变化及甲氰咪胍的影响

消炎痛可引起小鼠胃粘膜损伤,在一定剂量范围内,其剂量和胃粘膜损伤程度之间有明显的量效关系。在引起胃粘膜损伤时,胃组织胺含量相应增加,大剂量重度损伤时尤为明显。预先用甲氰咪胍灌胃,可明显减轻损伤并降低组织胺含量。提示组织胺参与消炎痛致胃粘膜损伤过程并对损伤产生一定影响。     

胃蛋白酶的适应性细胞保护作用及其机制

胃蛋白酶是否具有适应性细胞保护作用,尚不清楚。本工作观察了胃蛋白酶对牛磺胆酸所致的胃粘膜损伤的影响。酸性牛磺胆酸80mM 给禁食大鼠灌胃,90min 后可引起严重的胃粘膜损伤。胃蛋白酶225单位(U)溶于水、150U 溶于0.1N HCl 或75U 溶于0.2N HGl,三者分别作为“弱刺激”提前15min 灌胃,均可防止由牛磺胆酸所致胃粘膜的损伤;这种保护作用呈明显的量效关系,并可持续约90min 之久。消炎痛(一种前列腺素合成酶的抑制剂) 提前60min 皮下注射,可阻断胃蛋白酶的适应性细胞保护作用,如果皮下给予外源性前列腺素 E_2(PGE_2),则能使这一作用重新恢复。这些结果说明,弱的胃蛋白酶刺激具有对胃粘膜的适应性细胞保护作用,其产生机制可能是通过诱发内源性 PG 的合成和释放而实现的。     

花生油对酒精所致胃粘膜损伤的保护作用

着重研究了花生油对无水酒精所引起的大白鼠胃粘膜损伤的保护作用,并对花生油作用的有效部位和机制作了初步探讨。     

血清胃泌素变化与急性胃粘膜病变关系的研究

对大白鼠血清中胃泌素水平的变化与急性胃粘膜病变的关系进行了初步的研究,结果表明以消炎痛为诱因引起的急性胃粘膜病变大白鼠血清胃泌素水平明显增高。而维酶素可以抑制因消炎痛引起的急性胃粘膜病变时血清胃泌素的释放,对胃粘膜具有保护作用。     

适应性细胞保护作用与胃粘液-碳酸氢盐屏障的关系

本文观察了由天然或外源性弱刺激引起的适应性细胞保护作用与胃粘液-HCO_3~-屏障的关系,并分析了它的可能机制。结果表明,胃蛋白酶150单位(溶于0.1 mol/L 盐酸)或20%酒精灌胃,均可引起胃壁结合粘液分泌明显增加,并呈现明显的量效关系,一次处理后,作用可持续60min。这一作用可被消炎痛所阻断;给予外源性 PGE_2又可重新恢复。用醋唑酰胺阻断胃粘膜 HCO_3~-分泌,则上述两种弱刺激的保护作用均明显减弱。说明天然或外源性弱刺激通过诱发内源性 PGs 的合成和释放,使胃粘膜-HCO_3~-屏障的机能加强。这可能是它产生适应性细胞保护作用的机制之一。     

胃粘膜Na~+-K~+-Mg~(2+)-ATPase在适应性细胞保护机制中的作用

本文观察了胃粘膜(Na~+-K~+-Mg~(2+))-ATPase在适应性细胞保护机制中的作用,并分析了其与内源性PG的关系。结果表明,哇巴因(一种(Na~+-K~+-Mg~(2+))-ATPase的抑制剂)可部分抑制胃蛋白酶150U(溶于0.1mol/L盐酸中)和20％乙醇的适应性细胞保护作用,并呈现明显的量效关系。用上述两种弱刺激灌胃后15min,胃粘膜(Na~+-K~+-Mg~(2+))-ATPase活力明显升高,也呈现明显的量效关系。预先给予消炎痛以抑制内源性PG的合成,则可阻断弱刺激所诱发的胃粘膜(Na~+-K~+-Mg~(2+))-ATPase活力的升高;若在此基础上再给予外源性PGE_2,又可解除消炎痛的阻断作用。这些结果说明,弱刺激通过内源性PG,进而促进胃粘膜(Na~+-K~+-Mg~(2+))-ATPase活力升高,使粘膜抵抗损伤的能力增强,可能是其保护作用的重要机制之一。     

Differences in action of topical and systemic cysteamine on gastric blood flow,gastric acid secretion and gastric ulceration in the rat

The effect of cysteamine on gastric blood flow and on the indomethacin-induced gastric mucosal damage was studied. In anesthetized rats, cysteamine (280 mg/kg) given subcutaneously (sc) decreased gastric blood flow measured by the laser Doppler flowmetry technique. In contrast, cysteamine (1–60 mg/ml) applied topically to the serosal surface of the stomach evoked a concentration-dependent and long-lasting increase in gastric blood flow. At 60 mg/ml, cysteamine increased blood flow by 166.8 ± 26.1% of predrug control value. Pretreatment with indomethacin (20 mg/kg, sc), intravenous (iv) atropine (1 mg/kg), propranolol (1 mg/kg, iv), combined H₁ and H₂-blockade or bilateral cervical vagotomy alone or combined with iv guanethidine (8 mg/kg), or pretreatment with the capsaicin analogue resiniferatoxin did not reduce the vasodilator response to cysteamine. The vasodilator response to topical capsaicin, was not reduced after sc cysteamine (280 mg/kg) pretreatment. In conscious pylorus-ligated rats, sc cysteamine (100 or 280 mg/kg) given simultaneously with indomethacin inhibited gastric acid output but had variable effects on the indomethacin-induced gastric mucosal damage. Cysteamine (100 or 280 mg/kg) administered sc 4 h prior to indomethacin enhanced gastric injury by sc indomethacin, but did not prevent the gastroprotective action of capsaicin. In contrast, orally administered cysteamine (60 mg/ml) reduced gastric injury induced by sc indomethacin plus intragastric HCl. These data provide the first evidence for the effect of cysteamine on gastric microcirculation in the rat and suggest a direct vasodilator effect for topical cysteamine. The microvascular effects of cysteamine are largely responsible for the different effects of this agent on experimental gastric injury.     

Activation of central opioid receptors may induce gastric mucosal defence in the rat.

The effect of different opioid peptides on acidified ethanol- and indomethacin-induced gastric mucosal lesions was studied following intracerebroventricular (i.c.v.) administration. It was found that both the selective delta opioid receptor agonists--deltorphin II, [D-Ala(2), D-Leu(5)]-enkephalin (DADLE), [D-Pen(2), D-Pen(5)]-enkephalin (DPDPE)-, mu-opioid receptor agonist--[D-Ala(2), Phe(4), GlyT-ol]-enkephalin (DAGO)--as well as beta-endorphin inhibited the mucosal damage induced by both ethanol and indomethacin in pmolar dose range. In contrast, the gastric acid secretion was not influenced by DADLE in the dose of 16 nmol/rat and only a slight reduction (40%) was induced by DAGO in the dose of 1.9 nmol/rat. The protective effect was abolished in both ulcer models by bilateral cervical vagotomy. N(G)-nitro-L-arginine, an inhibitor of NO synthase, reduced the protective action in ethanol-induced, but not in indomethacin-induced gastric damage. The results suggest that activation of supraspinal delta and mu-opioid receptors resulted in inhibition of gastric mucosal lesions elicited by ethanol or indomethacin. The gastroprotective action is independent from the effect of opioids on acid secretion. Vagal nerve is involved in conveying the central action to the periphery. The mechanism of the gastroprotective effect of opioids is different in ethanol- and indomethacin-ulcer models: prostaglandins and nitric oxide are likely to be involved in the protective action of opioid peptides in ethanol-, but not in the indomethacin-ulcer model.     

Salicylic acid blocks indomethacin-induced cyclooxygenase inhibition and lesion formation in rat gastric mucosa

Salicylic acid has been shown to decrease gastric mucosal lesions induced by indomethacin in the rat. In vitro, it has also been shown to counteract the inhibitory effect of indomethacin and aspirin on the cyclooxygenase enzyme system in seminal vesicle microsomes and in platelets and vascular tissue. The hypothesis that the mechanism of salicylic acid "protection" against indomethacin-induced gastric lesions involves interference with indomethacin-induced mucosal cyclooxygenase inhibition was tested. Male, fasted rats were treated with intragastric salicylic acid in doses of 50, 100, 200, 300, or 400 mg/kg concomitantly with a sc injection of 20 mg/kg of indomethacin. Gastric mucosal lesions and mucosal cyclooxygenase activity (as measured by ex vivo prostaglandin F2 alpha synthesis) were examined 3 hr later. Intragastric salicylic acid, 200-400 mg/kg, significantly reduced indomethacin-induced lesion formation, while counteracting significantly indomethacin inhibition of prostaglandin synthesis. Salicylic acid alone did not significantly change cyclooxygenase activity. It is concluded that topical salicylic acid can decrease indomethacin-induced gastric mucosal lesion in the rat, in part, by counteracting the inhibitory effect of indomethacin at the cyclooxygenase level.     

Gastroprotective and Anti-oxidative Properties of Ascorbic Acid on Indomethacin-induced Gastric Injuries in Rats

Reactive oxygen species (ROS) have been implicated in the etiology of indomethacin-induced gastric mucosal damage. This study investigated ascorbic acid (vitamin C)'s protective effects against oxidative gastric mucosal damage induced by indomethacin. Ascorbic acid is a powerful antioxidant because it can donate a hydrogen atom and form a relatively stable ascorbyl free radical. We have investigated alterations in the levels of myeloperoxidase, antioxidant system enzymes (glutathione S-transferase, superoxide dismutase, glutathione reductase, catalase, glutathione peroxidase), lipid peroxidation and glutathione, as markers for ulceration process following oral administration of ascorbic acid, famotidine, lansoprazole, and ranitidine in rats with indomethacin-induced ulcers. In the present study, we found that (1) ascorbic acid, famotidine, lansoprazole and ranitidine reduced the development of indomethacin-induced gastric damages; (2) the administration of indomethacin caused a significant decrease in the levels of superoxide dismutase, glutathione peroxidase, glutathione S-transferase and glutathione, and an increase in the lipid peroxidation level; (3) the administration of ascorbic acid reversed the trend, inducing a significant increase of these enzymes' levels and a reduction in lipid peroxidation level in tissues; and (4) catalase, glutathione reductase and myeloperoxidase activities, increased by indomethacin, were found to be lower in the ascorbic acid, famotidine, lansoprazole and ranitidine-treated groups. The results indicate that the gastroprotective properties of ascorbic acid could be related to its positive effects on the antioxidant system and myeloperoxidase activity in indomethacin-induced gastric ulcers in rats.     

Anti-ulcerogenic action of a combination of a psychostimulator of the phenylalkylsydnone imine series and arginine]

It has been revealed that OF 743, one of the psychostimulators belonging to phenylalkylsydnonimine derivatives, exerts anti-ulcerogenic action in case of stress- and ethanol-induced damage of gastric mucosa in rats. However OF 743 was not effective in case of indomethacin-induced gastric mucosal damage. Complex administration of OF 743 and arginine was accompanied by a considerable decrease of indomethacin-induced gastric mucosal damage. That combination was more effective than OF 743 alone in case of ethanol-induced gastric mucosal damage.     

Evidence for the existence of gastric cytoprotective effect of atropine and cimetidine in humans

The effects of cimetidine (12.5 mg i.m.) and atropine (0.125 mg i.m.) were studied on the basal (BAO) and pentagastrin (6 micrograms X kg-1 s.c.)-stimulated (MAO) gastric acid secretion; the gastric mucosal microbleeding provoked by one-day treatment with indomethacin (4 X 25 mg orally) in patients with chronic disorders of the joints. The extent of the gastric microbleeding was measured by spectrophotometric determination of haemoglobin in gastric lavage fluid. The aims of this study were to determine the doses of cimetidine and atropine in humans without any significant inhibitory effects either on the basal or on the maximal gastric acid output to evaluate the cytoprotective action of these doses of cimetidine and atropine on the indomethacin-induced gastric microbleeding in the man. It was found that cimetidine (12.5 mg i.m.) and atropine (0.125 mg i.m.) did not cause any significant inhibition either of the BAO or of the MAO; indomethacin (4 X 25 mg orally) significantly increased gastric microbleeding in the patients; cimetidine and atropine, in the above doses, were able to prevent significantly indomethacin-induced gastric microbleeding in the patients. These results provide evidence for the existence of gastric cytoprotective effects of cimetidine and atropine in humans.     

Capsaicin-sensitive afferent sensory nerves in modulating gastric mucosal defense against noxious agents.

In the rat stomach, evidence has been provided that capsaicin-sensitive sensory nerves (CSSN) are involved in a local defense mechanism against gastric ulcer. In the present study capsaicin or resiniferatoxin (RTX), a more potent capsaicin analogue, was used to elucidate the role of these sensory nerves in gastric mucosal protection, mucosal permeability, gastric acid secretion and gastrointestinal blood flow in the rat. In the rat stomach and jejunum, intravenous RTX or topical capsaicin or RTX effected a pronounced and long-lasting enhancement of the microcirculation at these sites, measured by laser Doppler flowmetry technique. Introduction of capsaicin into the rat stomach in very low concentrations of ng-microg x mL(-1) range protected the gastric mucosa against damage produced by topical acidified aspirin, indomethacin, ethanol or 0.6 N HCl. Resiniferatoxin exhibited acute gastroprotective effect similar to that of capsaicin and exerted marked protective action on the exogenous HCl, or the secretagogue-induced enhancement of the indomethacin injury. The ulcer preventive effect of both agents was not prevented by atropine or cimetidine treatment. Capsaicin given into the stomach in higher desensitizing concentrations of 6.5 mM markedly enhanced the susceptibility of the gastric mucosa and invariably aggravated gastric mucosal damage evoked by later noxious challenge. Such high desensitizing concentrations of capsaicin, however, did not reduce the cytoprotective effect of prostacyclin (PGI2) or beta-carotene. Capsaicin or RTX had an additive protective effect to that of atropine or cimetidine. In rats pretreated with cysteamine to deplete tissue somatostatin, capsaicin protected against the indomethacin-induced mucosal injury. Gastric acid secretion of the pylorus-ligated rats was inhibited with capsaicin or RTX given in low non-desensitizing concentrations, with the inhibition being most marked in the first hour following pylorus-ligation. Low intragastric concentrations of RTX reduced gastric hydrogen ion back-diffusion evoked by topical acidified salicylates. It is concluded that the gastropotective effect of capsaicin-type agents involves primarily an enhancement of the microcirculation effected through local release of mediator peptides from the sensory nerve terminals. A reduction in gastric acidity may contribute to some degree in the gastric protective action of capsaicin-type agents. The vasodilator and gastroprotective effects of capsaicin-type agents do not depend on vagal efferents or sympathetic neurons, involve prostanoids, histaminergic or cholinergic pathways.